Abiopharma

Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

New Form 8-K - KIORA PHARMACEUTICALS INC Filed: 2025-08-08 AccNo: 0001372514-25-000064 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 10-Q - BICYCLE THERAPEUTICS PLC Filed: 2025-08-08 AccNo: 0001558370-25-010843 Size: 10 MB

New Form 8-K - Canopy Growth Corp Filed: 2025-08-08 AccNo: 0001193125-25-176020 Size: 4 MB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

New Form 8-K - BICYCLE THERAPEUTICS PLC Filed: 2025-08-08 AccNo: 0001104659-25-075435 Size: 332 KB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

New Form 8-K - Repare Therapeutics Inc. Filed: 2025-08-08 AccNo: 0000950170-25-105463 Size: 471 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Canopy Growth Press Release - Canopy Growth Reports First Quarter Fiscal 2026 Financial Results; Cannabis revenue increased 24% year-over-year

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

New Form 10-Q - KIORA PHARMACEUTICALS INC Filed: 2025-08-08 AccNo: 0001372514-25-000061 Size: 16 MB

New Form 8-K - Embecta Corp. Filed: 2025-08-08 AccNo: 0001872789-25-000025 Size: 864 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - Cingulate Inc. Filed: 2025-08-08 AccNo: 0001641172-25-022664 Size: 249 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility